Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance by unknown
RESEARCH Open Access
Machine learning to predict rapid
progression of carotid atherosclerosis in
patients with impaired glucose tolerance
Xia Hu1,2, Peter D. Reaven1,3,4, Aramesh Saremi3, Ninghao Liu2, Mohammad Ali Abbasi1, Huan Liu1,
Raymond Q. Migrino3,4* and the ACT NOW Study Investigators
Abstract
Objectives: Prediabetes is a major epidemic and is associated with adverse cardio-cerebrovascular outcomes. Early
identification of patients who will develop rapid progression of atherosclerosis could be beneficial for improved risk
stratification. In this paper, we investigate important factors impacting the prediction, using several machine learning
methods, of rapid progression of carotid intima-media thickness in impaired glucose tolerance (IGT) participants.
Methods: In the Actos Now for Prevention of Diabetes (ACT NOW) study, 382 participants with IGT underwent carotid
intima-media thickness (CIMT) ultrasound evaluation at baseline and at 15–18 months, and were divided into rapid
progressors (RP, n = 39, 58 ± 17.5 μM change) and non-rapid progressors (NRP, n = 343, 5.8 ± 20 μM change, p < 0.001
versus RP). To deal with complex multi-modal data consisting of demographic, clinical, and laboratory variables, we
propose a general data-driven framework to investigate the ACT NOW dataset. In particular, we first employed a Fisher
Score-based feature selection method to identify the most effective variables and then proposed a probabilistic
Bayes-based learning method for the prediction. Comparison of the methods and factors was conducted using
area under the receiver operating characteristic curve (AUC) analyses and Brier score.
Results: The experimental results show that the proposed learning methods performed well in identifying or
predicting RP. Among the methods, the performance of Naïve Bayes was the best (AUC 0.797, Brier score 0.085)
compared to multilayer perceptron (0.729, 0.086) and random forest (0.642, 0.10). The results also show that
feature selection has a significant positive impact on the data prediction performance.
Conclusions: By dealing with multi-modal data, the proposed learning methods show effectiveness in predicting
prediabetics at risk for rapid atherosclerosis progression. The proposed framework demonstrated utility in outcome
prediction in a typical multidimensional clinical dataset with a relatively small number of subjects, extending the
potential utility of machine learning approaches beyond extremely large-scale datasets.
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1 Introduction
Impaired glucose tolerance (IGT) is a risk factor for the
development of type 2 diabetes mellitus (T2DM) [1],
and both IGT and T2DM are associated with increase in
cardio-cerebrovascular related mortality [2, 3]. The Dia-
betes Epidemiology: Collaborative Analysis of Diagnostic
Criteria in Europe (DECODE) [4] study showed a tight
correlation between IGT and cardiovascular mortality, and
IGT is a known risk factor for early-stage atherosclerosis
[5]. In the Actos Now for Prevention of Diabetes (ACT
NOW) study, it was shown that pharmacotherapy with
pioglitazone in IGT subjects resulted in reduced develop-
ment of T2DM [6] as well as reduced progression of ath-
erosclerosis [7]. Therefore, identification of IGT subjects
who are at risk for rapid atherosclerosis progression, and
understanding the important characteristics that affect
the identification process, may be beneficial in risk
stratification and early intervention. Machine learning
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(ML) methods have been widely used to learn complex
relationships or patterns from data to make accurate
predictions [8] and are usually applied in the setting of
massive datasets (“big data”). Although encompassing
traditional biostatistical approaches such as linear regres-
sion modeling, ML approaches, in general, have advantages
over traditional frequentist statistical approaches because
they can predict patterns without any assumption that
simple/complex equations underlie relationships among
variables and are able to handle the high-dimensionality na-
ture of medical data [9, 10]. The use of ML approaches in
clinical trial data to predict clinical response remains in its
infancy. Recently, researchers used data from clinical trials
of major depressive disorders (STAR*D and COMED) to
predict whether a patient will reach clinical remission from
a major depressive episode following treatment with citalo-
pram using stochastic gradient boosting ML approach [11].
Using the data from 768 patients in the Neo-tAnGo
chemotherapy clinical trial for breast cancer, ML methods
were used to classify cells as cancerous or not [12]. The
ACT NOW clinical trial has contributed to novel discover-
ies on reducing the onset of type 2 diabetes mellitus in at-
risk participants using pioglitazone [6] as well as providing
insights as to underlying metabolic mechanisms involved
with development of diabetes [13–15], but the analytic ap-
proaches used involved traditional frequentist biostatistical
methods. This study aims to investigate the effectiveness of
different ML based methods in predicting IGT patients
who will develop rapid carotid atherosclerosis plaque pro-
gression in a limited dataset typical of clinical trials.
2 Methods
2.1 Study design and subjects
The ACT NOW study design including the exclusion
and inclusion criteria have been previously published
(Clinicaltrials.gov NCT00220961) [6, 13]. In brief, the ACT
NOW study was a multicenter, prospective, randomized,
double-blind, placebo-controlled trial to test whether
pioglitazone prevents T2DM and progression of carotid
intima-media thickness (CIMT) in adults ≥18 years old
with IGT (defined by a 2-h plasma glucose concentration
of 140–199 mg/dL during a 75 g, 2-h oral glucose toler-
ance test). Of the 602 total participants, 382 subjects had
serial carotid atherosclerosis measurements and comprise
the study population of the current study. All research
subjects gave informed consent and the study was ap-
proved by the Institutional Review Boards at each site.
2.2 Carotid atherosclerosis measurement and progression
classification
The method for measurement of carotid atherosclerosis
has previously been reported [7]. In brief, all 382 sub-
jects underwent high-resolution B-mode carotid artery
ultrasound (Logiq, General Electric, Waukesha, WI) to
image the far wall of the right distal common carotid
region at baseline and mid-study (15–18 months after
baseline). Carotid intima-media thickness (CIMT) was
measured, and the absolute difference in CIMT between
the two time points was considered the measure of
plaque progression (or regression). Subjects with CIMT
change in the top decile (n = 39, 58.1 ± 17.5 μM change
from baseline) were arbitrarily classified as rapid pro-
gressors (RP), and the rest (n = 343, 5.8 ± 2.0 μM change
from baseline, p < 0.001 versus RP) were considered
non-rapid progressors (NRP). Note that despite the arbi-
trary nature of the cutoff selection, the CIMT change
observed in the RP group (58.1 ± 17.5 μM) represents
more than 2 standard deviations of annual CIMT change
(11.8 ± 12.8 μM) reported in the Multi-Ethnic Study of
Atherosclerosis (MESA) study involving 3441 subjects
with multiple cardiovascular disease risk factors [16],
providing support for the categorization of this group as
rapid progressors.
Demographic, clinical, and laboratory information was
collected as previously reported [6, 13] and used as vari-
ables for model building.
2.3 Data analytics framework
2.3.1 Data analyses settings
2.3.1.1 Notations Boldface uppercase letters (e.g., A)
are used to denote matrices, uppercase letters (e.g., A) to
denote vectors, and lowercase letters (e.g., a) to denote
scalars. The entry at the ith row and jth column of a
matrix A is denoted as Aij. Ai∗ and A∗j denote the ith row
and jth column of a matrix A, respectively.
Given a set of patients X ∈ℝn × d, n is the number of
patients and d is the number of features. The feature (at-
tribute, variable) vector is denoted as {X1, X2, …, Xd}.
Let Y ∈ ℝn be a vector denoting the classes of the pa-
tients. In this study, we have two classes for each patient,
i.e., Yi used in Hu et al. study [17].
With the notations above, the problem is formally de-
fined as follows: given a set of patients X with their class
information Y, the aim is to learn a classifier h to auto-
matically assign class labels for unseen patients (i.e., test
data).
2.3.1.2 Preprocessing Data preprocessing was per-
formed to make the input data more consistent to facili-
tate machine learning algorithms. First, data imputation
was performed to deal with missing values. Missing
value was crudely imputed as the smallest value for the
variable in the dataset. Second, in order to tackle vari-
ables with heterogeneous nature, a widely used method
[18] was employed to create dummy variables to substi-
tute all possible categories in a categorical variable. Zero
or 1 was used to indicate the absence or presence of a
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categorical variable, thus creating multiple dummy vari-
ables for the categorical variable. The number of dummy
variables is equal to the number of distinct categories in
the original variable.
The variables used in the model are as follows: age;
sex; race; Hispanic race; site; family income; randomization
to placebo versus pioglitazone; waist circumference; height;
systolic/diastolic/mean blood pressure; body mass index;
plasma creatinine; urine microalbumin; insulin level;
interleukin-6; leptin; plasminogen activator inhibitor-1; C-
reactive protein; monocyte chemoattractant protein-1;
tumor necrosis factor-1; total cholesterol; triglyceride; low
density lipoprotein; alkaline phosphatase; alanine trans-
aminase; aspartate transaminase; hemoglobin; hematocrit;
platelet; white blood cell count; and history of hypertension,
smoking, the use of alcohol, the use of lipid lowering ther-
apy, the use of nonsteroidal anti-inflammatory medication,
the use of angiotensin converting enzyme inhibitor, gesta-
tional diabetes, myocardial infarction, stroke, and peripheral
vascular disease.
2.3.1.3 Feature selection with Fisher Score To deal
with the multi-modal data consisting of heterogeneous
variables, we propose to employ feature selection to first
obtain an effective feature space. By introducing feature
selection in the learning framework, we exploit its ad-
vantages including increased learning performance and
computational efficiency, better generalization of the
learned model, and interpretability for specific applica-
tions. In particular, we employed a supervised feature se-
lection algorithm called Fisher Score in our study. Fisher
Score [19], which is one of the most widely used methods,
has shown effectiveness in many data mining applications.
The basic idea is to select the features that are efficient for
discrimination, i.e., feature values of samples within a class
are small while being large between classes. The top k fea-
tures can be obtained with a greedy search method by
finding the features with the largest Fisher Scores. Human
(clinician) input mainly involved consideration of which
redundant/repetitive features are to be discarded (e.g., the
presence of hypertension variable and the use of antihy-
pertensive medications variable) and which features are ir-
relevant to predictive function (e.g., clinical trial variables
that were measured after the 18-month outcome has
occurred). The investigators were careful in minimizing
feature de-selection so as to minimize bias and prevent
exlcusion in the model of previously unknown features
that could affect the outcome of interest.
2.3.1.4 A probabilistic Bayes model We employ a
probabilistic Bayes model to tackle the classification
problem. Bayesian classifiers have been intensively studied
to assign the most likely class to a given data instance
represented by its feature vector. The classifiers are built
upon the Bayes theorem shown as below:
P Y jX1X2…Xdð Þ ¼ P X1X2…XdjYð ÞP Yð ÞP X1X2…Xdð Þ ; ð1Þ
where P Y jX1X2…Xdð Þ represents the probability of hav-
ing class label Y given the data instance X ¼ X1X2…Xdf g,
P X1X2…XdjYð Þ represents the probability to observe
X ¼ X1X2…Xdf g in the class Y, P Yð Þ represents the
probability that instances belong to the class Y, P
X1X2…Xdð Þ is the probability of instance X. To use
Bayes theorem for classification, the goal is to find the
class, give an instance X ¼ X1X2…Xdf g, to maximize the
posterior probability, shown below:
h xð Þ ¼ argmaxc P Y ¼ cjx ¼ X1X2…Xdð Þ: ð2Þ
Since the prior probability P X1X2…Xdð Þ is a fixed
value in Eq. 1, by substituting Eq. 2 into Eq. 1, it is easy
to show that P(Y|X1X2…Xd) ∝ P(X1X2…Xd|Y)P(Y), in-
dicating that the posterior probability is proportional to
likelihood times prior. Therefore, given a data instance x ,
its class label can be determined according to the follow-
ing Bayes classifier:
h xð Þ ¼ argmaxc P x ¼ X1X2…XdjY ¼ cð ÞP Y ¼ cð Þ;
ð3Þ
which is to maximize the multiplication of likelihood
and prior previously discussed. However, the calculation
of likelihood P x ¼ X1X2…XdjY ¼ cð Þ may be difficult
especially when the number of data instances is small.
To make the computation effective and efficient, a
widely used assumption for Bayesian classifiers is that
the features are independent with each other given the
classes shown as follows:
P x ¼ X1X2…XdjY ¼ cð Þ
¼ P X1jY ¼ cð ÞP X2jY ¼ cð Þ…P XdjY ¼ cð Þ:
ð4Þ
The classifier built upon this assumption is Naïve
Bayes and while the assumption is simple, Naïve Bayes
classifier has shown effectiveness in many real-world ap-
plications such as text classification [20] and information
retrieval [21]. Naïve Bayes classifier was used in the
current study by substituting Eq. 4 into Eq. 3, shown as
below:
h xð Þ ¼ argmaxc
Yd
i
P XijY ¼ cð ÞP Y ¼ cð Þ: ð5Þ
The proposed method is efficient in terms of training
and testing time. Although the real-world dataset the
method was used in contains a limited number of subjects,
the proposed method has the potential to be applied on a
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large-scale dataset based on the time complexity analysis
as follows: training time of the proposed method is
O(|D|Ld + |C||V|), where |D| is the number of instances
in the training data, Ld is the average number of variables
of a subject in the training data, and |C| is the number of
classes and |V| is the number of variables. Testing time of
the proposed method is O(|C| Lt), where Lt is the average
number of variables of a subject in the testing data.
In addition to Bayesian classifiers, in the pilot study,
we also employed another two representative machine
learning methods, multilayer perceptron (MLP) and ran-
dom forest (RF), for classification. MLP is a supervised
learning model that uses backpropagation for training an
artificial neural network. The learned model consists of
multiple layers of nodes, and each layer is fully connected
to the next one. The key idea is that, by constructing mul-
tiple layers of the model, MLP aims to better map sets of
input data onto a set of appropriate outputs. RF is a repre-
sentative ensemble learning method that constructs a
multitude of decision trees for classification. Comparing
to traditional decision tree-based learning models, RF is
more robust to the overfitting problem and much more
effective by combining multiple models. Similarly, RF
enjoys the nice properties of decision tree based models
such as the interpretability and fast learning rate.
2.3.1.5 Assessment of model performance The perfor-
mances of the three ML models were assessed using area
under the receiver operating characteristic curve (AUC)
and Brier score. The Brier score is a proper score func-
tion that measures the accuracy of the probabilistic pre-
dictions, with a score of 0 being perfect prediction and a
score of 1 being worst score achievable [22]. The AUC
was calculated from the probability of RP classification
for each subject using each of the learning methods. The
Brier score was computed as the mean squared difference
between final classification prediction for each subject ver-
sus ground truth subject classification [22].
3 Results
3.1 Clinical and demographic characteristics
Clinical, demographic, and CIMT data are presented in
Table 1. There was no significant difference in age, gender,
cardiovascular risk factor co-morbidities, and proportion
Table 1 Demographic and clinical and laboratory results
All Rapid progressors Non-rapid progressors p value
(n = 382) (n = 39) (n = 343)
Age (years) 53.6 ± 0.6 54.1 ± 1.6 53.5 ± 0.6 NS
Female gender (%) 54.19 64.10 53.06 NS
Hispanic race (%)* 31.15 15.38 32.94 0.039
Enrollment site* 382 39 343 <0.001
Site 1 80 5 75
Site 2 46 15 31
Site 3 54 1 53
Site 4 46 7 39
Site 5 45 8 37
Site 6 83 3 80
Site 7 28 0 28
Hypertension (%) 248 (64.9 %) 21 (53.8 %) 227 (66.2 %) NS
On lipid lowering therapy (%) 123 (32.4 %) 9 (23.1 %) 114 (33.4 %) NS
Known vascular disease (%) 7 (1.8 %) 0 (0 %) 7 (2.0 %) NS
Weight (kg) 92.8 ± 0.9 90.1 ± 2.6 93.1 ± 0.9 NS
Mean arterial pressure (mmHg) 90.7 ± 0.6 90.9 ± 1.6 90.7 ± 0.6 NS
HbA1c (%) 5.48 ± 0.02 5.37 ± 0.05 5.50 ± 0.02 NS
Plasma creatinine* 0.74 ± 0.02 0.87 ± 0.3 0.72 ± 0.03 0.025
Urine mean microalbumin* 14.6 ± 1.0 11.0 ± 2.7 15.0 ± 1.1 0.019
PAI-1* 15.2 ± 0.5 14.7 ± 3.1 15.2 ± 0.4 0.02
Pioglitazone treatment (%) 49.21 46.15 49.56 NS
Baseline CIMT (μM) 759 ± 8 750 ± 29 760 ± 08 NS
Change in CIMT (μM)* 11.1 ± 25.9 58.0 ± 17.5 5.8 ± 17.5 <0.001
*p < 0.05; NS- not significant, HbA1c- glycated hemoglobin, PAI-1-plasminogen activator inhibitor-1, CIMT-carotid intima-media thickness
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assigned to pioglitazone between the RP and NRP groups.
There were significant differences in enrollment site, pro-
portion with Hispanic race, urine microalbumin, plasma
creatinine and serum plasminogen activator inhibitor-1
level between RP and NRP.
3.2 Feature selection results
Based on Fisher Scores, the following variables were se-
lected based on the feature selection process: hemoglobin
(HGB), mean plasma creatinine (MEAN_PCREAT),
PCREAT, gestational diabetes (GDM)_Y_dummy, arterial
procedures (OpArtery)_N_dummy, OpArtery_Y_dummy,
medical center (CURRENTCENTER), SITE, GDM_N_
dummy, Ethnicity_Hispanic (H)_dummy, and HISPANIC,
Ethnicity_Non-Hispanic (N)_dummy. However, since
CURRENTCENTER and SITE are redundant features, we
eliminate SITE from the feature set that are fed into the
learning phase. We also removed PCREAT because it is
redundant with Mean PCREAT. It also demonstrates the
importance of incorporating domain knowledge into the
proposed data-driven framework. More sophisticated
domain knowledge, such as group structure of the fea-
tures or pair-wise partial order between some features,
could be further incorporated in the framework to im-
prove the learning performance. Since it is beyond the
scope of this work, we leave it as future work.
3.3 Learning performance of the baseline methods
We evaluated the performance of several representative
learning methods with threefold cross validation. In par-
ticular, the data were randomly divided into a training set
(67 % of subjects) whose data were used to build the model,
and a test set (33 % of subjects) whose data were used to
validate the built model. While each of the methods had
good performance overall, Naïve Bayes with feature selec-
tion achieved the best performance, which resulted in cor-
rect classification in 340 of 382 subjects (89.23 %), AUC of
0.797 and Brier score of 0.086 (Table 2).
Also, we investigated the effectiveness of introducing
feature selection method in the data analytics framework.
The experimental results showed that all of the three
methods achieved significantly better results by using
feature selection, and Naïve Bayes method achieved
AUC of 0.797 (with feature selection) and 0.745 (without
feature selection).
4 Discussion
The novel finding of our study is that machine learning
methods can be applied to a limited dataset typical of a
clinical trial in order to predict impaired glucose tolerance
subjects who will develop rapid carotid plaque progression
with overall good performance. Our results demonstrate
the potential utility of sophisticated Bayesian approaches
in predicting clinical events from limited clinical datasets.
In 2010, approximately 1 in 3 adults in the USA or
about 79 million people had prediabetes [23], which in-
cludes IGT and impaired fasting glucose. Aside from the
risk for developing diabetes, prediabetes by itself is also
independently associated with future risk of stroke [24].
It is therefore critical that we develop tools for early
identification of at-risk patients who might benefit from
targeted early intervention, both non-pharmacologic and
pharmacologic.
The medical field remains almost universally reliant
on traditional frequentist low-dimensional statistical ap-
proaches for building risk prediction models [9], such as
linear and logistic regression models. These approaches
are disadvantaged by their reliance on the assumption
that simple or complex equations underlie the relation-
ships among variables and the limitations imposed by
the high dimensionality of hundreds of features/variables
typical of clinical trials or human studies. Machine learn-
ing approaches have the potential to overcome these dis-
advantages. Machine learning is the study of computer
algorithms and optimization techniques that can learn
complex relationships or patterns from data which in
turn can be used to make accurate predictions or decisions
[10]. Pattern recognition ML algorithms can be useful for
prediction even if no mathematical relationship exists
among variables and ML approaches can apply in infinite
dimensional spaces. Additionally, the testing of model per-
formance derived from a training set to a separate held-out
validation set enhances generalizability of the prediction
model allowing for a dynamic ability to learn from new data
to optimize the prediction model. Although its current use
is predominantly on massive datasets in social media,
Table 2 Performance of baseline models
Performance
parameter
Ml Naïve Bayes with
feature selection












AUC 0.797 0.745 0.711 0.703 0.736 0.703
Correctly classified
cases
340 (89.2 %) 290 (75.9 %) 339 (88.7 %) 330 (86.4 %) 338 (88.5 %) 343 (89.8 %)
Incorrectly
classified cases
42 (10.8 %) 92 (24.1 %) 43 (11.3 %) 52 (13.6 %) 44 (11.5 %) 39 (10.2 %)
Brier score 0.085 0.222 0.086 0.105
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finance, and information technology business applications,
ML may also be useful in high-dimensional but limited
dataset (in terms of number of subjects) typical of human
studies and clinical trials. In addition, the widespread use of
electronic medical records from large health care systems
to small independent clinical practices point to an ever-
increasing need for novel methods to analyze complex big
data. Our results support the use and application of ML ap-
proaches to predict outcomes in a limited dataset but with
a large number of demographic, clinical, and laboratory var-
iables. It is important to note that even though we used our
ML methods in a clinical dataset with a limited number of
subjects, we expect the approaches to perform well, if not
better, with a large number of subjects. A larger number of
subjects (bigger dataset) allows more robust cross validation
of model performance to a held-out dataset that would en-
hance the generalizability of the model. The major problem
of clinical trials, however, lies not in too large a sample size
but often the opposite, the smaller number of subjects en-
rolled. This is due to the cost of performing clinical trials
plus the ethical mandate of enrolling only the number of
subjects that is predicted to statistically show significant dif-
ferences among treatment options and no more, to ensure
research subject safety. Traditional frequentist biostatistical
approaches currently being used by the medical community
are limited by the dual conditions of small sample size and
hyperdimensional datasets typically present in real-world
clinical trials, which are conditions that may be ideally ad-
dressed by ML approaches, as we have shown in this study.
Among several learning methods used, we found that
Naïve Bayes with feature selection performed the best.
This is likely because probabilistic Bayesian models
perform well with multi-modal data because it assumes
independence in inferring probability of each feature. A
strong assumption of Naïve Bayes model is that the fea-
tures are conditionally independent given the label. The
assumption may not always hold true for clinical data,
but we believe this assumption is reasonable for this
study because of the following reasons. First, the condi-
tional independence is a relaxation to enable the calcu-
lation of conditional probability, but it is not strictly
required for using the model. Naïve Bayes model has
been widely used in many real-world problems in which
the assumption may not hold, and it achieved better per-
formance in our study compared with other methods. Sec-
ond, some features in our data, although not all of them,
are conditionally independent with each other given the
label, e.g., age and gender. A potentially interesting exten-
sion of this work and a promising future direction is to in-
vestigate how the conditional dependencies can be
learned and modeled in the Bayes-based models. The
findings motivate us to explore even more sophisticated
probabilistic Bayesian models in future work to im-
prove the proposed framework.
We were able to achieve several nice properties by
employing feature selection in the data analytics frame-
work. First, we achieved improved performance by introdu-
cing feature selection and demonstrated that feature
selection has the potential to improve this type of clinical
investigation by finding the most effective set of variables.
Second, by reducing the number of variables (ten variables
in our study), the approach allowed clinicians to manually
examine the selected variables and thus improved the inter-
pretability of the learned model. Third, with limited num-
ber of selected variables, we could now apply the proposed
framework on larger scale datasets that were previously
difficult to process with high-dimensional data.
The proposed framework, including preprocessing,
feature selection and prediction, is general and can be
easily extended to many other data-driven problems in
clinical research under some specific conditions. First, a
strong assumption in Naïve Bayes based methods is that
the features are conditionally independent given the
label. To extend the proposed model, we need to have a
good understanding of the nature of features. Second,
clinician input was incorporated in feature selection for
use in the model. Different problems/datasets may require
very different domain knowledge to select more inform-
ative or useful features. Applying the proposed framework
from this initial study to other problems/datasets is poten-
tially important and is one of our future goals.
An important limitation of the study is the inability to
determine the generalizability of the ML models derived
from the ACT NOW dataset to other prediabetic groups
or populations, which should be the focus of future studies
looking at real-world performance of ML approaches. This
limitation, however, is intrinsic to the nature of clinical tri-
als whose findings or conclusions need to be validated in
the general clinical population. Also, given large number
of variables before feature selection, it is difficult to model
and incorporate domain knowledge from physicians into
the framework.
5 Conclusions
In conclusion, ML methods were applied to a clinical trial
dataset and showed good performance in identifying/
predicting impaired glucose tolerance participants who
developed rapid carotid plaque progression. Naïve Bayes
method showed superior performance over multilayer
perceptron and random forest methods and feature
selection improved predictive performance. Our findings
point to the utility of ML methods in data analytics for
clinical applications.
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